Outcome of relapse in lupus nephritis:: Roles of reversal of renal fibrosis and response of inflammation to therapy

被引:58
作者
Hill, GS
Delahousse, M
Nochy, D
Thervet, É
Vrtovsnik, F
Rémy, P
Glotz, D
Bariéty, J
机构
[1] Hop Broussais, F-75674 Paris, France
[2] Hop St Louis, INSERM, U430, Paris, France
[3] Hop Bichat, F-75877 Paris, France
[4] Hop Henri Mondor, F-94010 Creteil, France
关键词
renal relapse; interstitial fibrosis; glomerular scarring; systemic lupus erythematosus; progressive renal disease;
D O I
10.1046/j.1523-1755.2002.00357.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Renal relapse in lupus nephritis has been shown to have ominous prognostic significance with the majority of patients progressing to doubling of serum creatinine (CRX2). However, not all patients do so. This report explores the roles of response of inflammation to therapy and of glomerular scarring and interstitial fibrosis and their potential reversal to outcome of renal relapse. Methods. Renal biopsies from 71 patients with lupus nephritis with an initial biopsy (Bx1) and systematic control biopsy (Bx2) after six months of therapy, as well as subsequent biopsies for clinical indications, were studied. The relationships of morphologic factors to renal relapse and its outcome as well as to CRX2 and end-stage renal disease (ESRD) were analyzed. Cox proportional hazards modeling was used to assess association of morphologic variables with outcomes. Results. Renal interstitial fibrosis and glomerular segmental scarring were partially reversible in 17 and 11 patients, respectively. This decline was associated with an excellent prognosis, with only one patient in each group (5.9% and 9.1% respectively) progressing to CRX2. All 18 patients who progressed to CRX2 either failed to respond to therapy (7 patients) as defined by normalization of serum creatinine (S-Cr ) and reduction of proteinuria to less than or equal to1 g/day, or relapsed after initial response (11 patients), as defined by recent rise of S-Cr >50% and/or proteinuria>3.5 g/day. However, relapse also occurred in 11 of 47 other patients without progression to CRX2. These patients showed a greater initial response of inflammation and deposits to therapy and fibrous lesions partially reversed in the period prior to relapse, so that active lesions were superimposed on a lower level of chronic lesions. By contrast, chronic lesions mounted steadily in those who progressed to CRX2. Cox proportional hazards modeling indicated a strong association of inflammatory variables with renal relapse, CRX2 and ESRD. However, the extent of immunoglobulin deposits was not significantly associated with any outcome. Finally, we found that failure of disease to remit also is associated with a high rate of CRX2 (64.8% vs. 13.0%, P = 0.00034). Conclusions. Interstitial fibrosis and glomerular scarring in systemic lupus erythematosus are partially reversible, and this reversal is attended by an excellent outcome. The outcome of renal relapse is determined by the initial response of inflammatory and chronicity elements to therapy, those with prior partial reversal of interstitial and glomerular scarring having a good outcome, and those in whom fibrotic lesions have continued to increase and have a poor outcome. Inflammatory variables appear to be more important in determining outcome than immunoglobulin deposits.
引用
收藏
页码:2176 / 2186
页数:11
相关论文
共 46 条
[1]  
ABOUNA GM, 1983, LANCET, V2, P1274
[2]  
Akahoshi M, 1999, ARTHRITIS RHEUM, V42, P1644, DOI 10.1002/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO
[3]  
2-L
[4]   LONG-TERM FOLLOW-UP OF PATIENTS WITH LUPUS NEPHRITIS - A STUDY BASED ON THE CLASSIFICATION OF THE WORLD-HEALTH-ORGANIZATION [J].
APPEL, GB ;
COHEN, DJ ;
PIRANI, CL ;
MELTZER, JI ;
ESTES, D .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (05) :877-885
[5]   PREDICTING RENAL OUTCOMES IN SEVERE LUPUS NEPHRITIS - CONTRIBUTIONS OF CLINICAL AND HISTOLOGIC DATA [J].
AUSTIN, HA ;
BOUMPAS, DT ;
VAUGHAN, EM ;
BALOW, JE .
KIDNEY INTERNATIONAL, 1994, 45 (02) :544-550
[6]  
AUSTIN HA, 1995, NEPHROL DIAL TRANSPL, V10, P1620
[7]  
AUSTIN HA, 1984, KIDNEY INT, V25, P689, DOI 10.1038/ki.1984.75
[8]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[9]  
Chan O, 1998, J IMMUNOL, V160, P51
[10]   The central and multiple roles of B cells in lupus pathogenesis [J].
Chan, OTM ;
Madaio, MP ;
Shlomchik, MJ .
IMMUNOLOGICAL REVIEWS, 1999, 169 :107-121